Article Type : Review Article
Authors : Addi RA, Benksim A and Cherkaoui M
Keywords : Covid-19; Sars-Cov2; Pneumonia; Omicron; Xbb.1.16; Arcturus; Variant
Coronavirus disease 2019 has brought about
a great threat to global public health.
More than 762 million confirmed cases have been reported according to
the statistics of the World Health Organization (WHO), including over 6 million
deaths. By the end of February 2023, an XBB sublineage named XBB.1.16 emerged
and was detected in various countries especially India, USA and UK. XBB.1.16
had an effective reproduction number (Re) that was 1.27 and 1.17 times higher
than XBB.1 and XBB.1.5, respectively. Also, XBB.1.16 is very resistant to a
variety of antiSARS-CoV-2 antibodies as well as XBB.1 and XBB.1.5. We conclude
that we could face a new pandemic in the coming months. Coronavirus disease
2019 (COVID-19) has brought about a great threat to global.
Coronavirus disease 2019 has brought about a great
threat to global public health. More
than 762 million confirmed cases have been reported according to the statistics
of the World Health Organization (WHO), including over 6 million deaths. By the
end of February 2023, an XBB sublineage named XBB.1.16 emerged and was detected
in various countries especially India, USA and UK. XBB.1.16 had an effective
reproduction number (Re) that was 1.27 and 1.17 times higher than XBB.1 and
XBB.1.5, respectively. Also, XBB.1.16 is very resistant to a variety of
anti-SARS-CoV-2 antibodies as well as XBB.1 and XBB.1.5. We conclude that we
could face a new pandemic in the coming months. Coronavirus disease 2019
(COVID-19) has brought about a great threat to global
Public health that has been surging for almost 4
years. More than 762 million confirmed
cases have been reported according to the statistics of the World Health
Organization (WHO), including over 6 million deaths [1]. By the end of February
2023, certain sublineages of the SARS-CoV-2 omicron XBB variant harboring the
F486P substitution in the spike (S) protein (e.g. XBB.1.5 and XBB.1.9) were
predominant worldwide [2]. Therefore, an XBB sublineage named XBB.1.16 emerged
and was detected in various countries especially India, USA and UK [3]. There
are 2 substitutions at the S protein in XBB.1.16: E180V in the N-terminal
domain, and T478R in the receptor-binding domain Compared to XBB.1.5. Also,
XBB.1.16 has two substitutions in the S protein: E180V is in the N-terminal
domain, and T478R in the receptor-binding domain Compared to XBB.1.5. XBB.1.16
had an effective reproduction number (Re) that was 1.27 and 1.17 times higher
than XBB.1 and XBB.1.5, respectively, suggesting that XBB.1.16 will spread
worldwide in a near future [4,5]. Also, the WHO classified XBB.1.16 as a
variant under surveillance on March 30, 2023. In addition, a strong resistance
of XBB.1.16 to BA.2 breakthrough infection sera and BA.5 was shown by
neutralization tests [4-7]. A recent study suggests that XBB.1.16 is very
resistant to a variety of anti-SARS-CoV-2 antibodies as well as XBB.1 and
XBB.1.5 [4]. The same study suggests that compared to XBB.1 and XBB.1.5,
XBB.1.16 has a greater growth advantage in the human population, while
XBB.1.16's ability to exhibit deep immune evasion is comparable to XBB.1 and
XBB.1.5. The acquired ability of XBB.1.16 may be due to different antigenicity
of XBB.1.5; and/or mutations in the non-S viral protein(s) which may contribute
to increased viral growth efficiency (4.7). This may lead us to conclude that
we could face a new pandemic in the coming months. What we need to do is stop
the spread of the XBB.1.16 or arcturus variant virus by (1) maintaining
prevention measures including wearing masks, frequent ventilation, keeping
physical distance, and washing hands; (2) developing variant-specific vaccines
or vaccines containing several mutations which may be used to prevent the
XBB.1.16 infection and transmission.
The authors want to acknowledge the Editorial office of the journal and all the anonymous reviewers.
The authors declare no conflict of interest.
Literature search, manuscript preparation and editing
was done by R.A.A, manuscript review was carried out by A.B. The supervision
was done by M.C and the whole manuscript was read and approved by all the
author`s.